| [1] |
Wiley SR, Schooley K, PJ Smolak, et al. Identification and characterization of a new member of the TNF family that induces apoptosis[J]. Immunity, 1995, 3(6): 673-82.
|
| [2] |
Gura T. How TRAIL kills cancer cells, but not normal cells[J]. Science, 1997, 277(5327): 768.
|
| [3] |
Fiorucci G, Vannucchi S, Chiantore MV, et al. TNF-related apoptosis-inducing ligand(TRAIL) as a pro-apoptotic signal transducer with cancer therapeutic potential[J]. Curr Pharm Des, 20 05, 11(7): 933-44.
|
| [4] |
Menke C, Bin L, Thorburn J, et al. Distinct TRAIL resistance mechanisms can be overcome by proteasome inhibition but not generally by synergizing agents[J]. Cancer Res, 2011, 71(5): 18 83-92.
|
| [5] |
Belkhiri A, Zhu S, Chen Z, et al. Resistance to TRAIL is mediated by DARPP-32 in gastric cancer[J]. Clin Cancer Res, 2012, 18(14): 38 89-900.
|
| [6] |
Song IS, Jun SY, Na HJ, et al. Inhibition of MKK7-JNK by the TOR signaling pathway regulator-like protein contributes to resistance of HCC cells to TRAIL-induced apoptosis[J]. Gastroenterology, 2012, 143(5): 1341-51.
|
| [7] |
Tomek S, Horak P, Pribill I, et al. Resistance to TRAIL-induced apoptosis in ovarian cancer cell lines is overcome by co-treatment with cytotoxic drugs[J]. Gynecol Oncol, 2004, 94(1): 107-14.
|
| [8] |
Zhou C, Qiu L, Sun Y, et al. Inhibition of EGFR/PI3K/AKT cell survival pathway promotes TSA’s effect on cell death and migration in human ovarian cancer cells[J]. Int J Oncol, 2006, 29 (1): 269-78.
|
| [9] |
Taghiyev AF, Guseva NV, Sturm MT, et al. Trichostatin A(TSA) sensitizes the human prostatic cancer cell line DU145 to death receptor ligands treatment[J]. Cancer Biol Ther, 2005, 4(4): 382-90.
|
| [10] |
Armeanu S1, Pathil A, Venturelli S, et al. Apoptosis on hepatoma cells but not on primary hepatocytes by histone deacetylase inhibitors valproate and ITF2357[J]. J Hepatol, 2005, 42(2): 210-7.
|
| [11] |
Jasek E, Lis GJ, Jasinska M, et al. Effect of histone deacetylase inhibitors trichostatin A and valproic acid on etoposide-induced apoptosis in leukemia cells[J]. Anticancer Res, 2012, 32(7): 2791-9.
|
| [12] |
Nakamura M, Saito H, Ebinuma H, et al. Reduction of telomerase activity in human liver cancer cells by a histone deacetylase inhibitor[J]. J Cell Physiol, 2001, 187(3): 392-401.
|
| [13] |
Carlisi D, Vassallo B, Lauricella M, et al. Histone deacetylase inhibitors induce in human hepatoma HepG2 cells acetylation of p53 and histones in correlation with apoptotic effects[J]. Int J Oncol, 2008, 32(1): 177-84.
|
| [14] |
Ganslmayer M, Konturek P, Herold C, et al. Antitumoral efficacy of four histone deacetylase inhibitors in hepatoma in vitro and in vivo[J]. Anticancer Res, 2012, 32(12): 5263-9.
|
| [15] |
Patiño-García A, Zalacain M, Folio C, et al. Profiling of chemonaive osteosarcoma and paired-normal cells identifies EBF2 as a mediator of osteoprotegerin inhibition to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis[J]. Clin Cancer Res, 2009, 15(16): 5082-91.
|
| [16] |
Mucha SR, Rizzani A, Gerbes AL, et al. JNK inhibition sensitises hepatocellular carcinoma cells but not normal hepatocytes to the TNF-related apoptosis-inducing ligand[J]. Gut, 2009, 58(5): 688-98.
|
| [17] |
Yamanaka T, Shiraki K, Sugimoto K, et al. Chemotherapeutic agents augment TRAIL-induced apoptosis in human hepatocellular carcinoma cell lines[J]. Hepatology, 2000, 32(3): 482-90.
|
| [18] |
Chen LF, Greene WC. Shaping the nuclear action of NFkappaB[ J] Nat Rev Mol Cell Biol, 2004, 5(5): 392-401.
|
| [19] |
Motoyama M, Yamazaki S, Eto-Kimura A, et al. Positive and negative regulation of nuclear factor-kappaB-mediated transcription by IkappaB-zeta, an inducible nuclear protein[J]. J Biol Chem, 2005, 280(9): 7444-51.
|
| [20] |
Kim YS, Schwabe RF, Qian T, et al. TRAIL-mediated apoptosis requires NF-kappaB inhibition and the mitochondrial permeability transition in human hepatoma cells[J]. Hepatology, 2002, 36(6): 14 98-508.
|
| [21] |
Ehrhardt H, Fulda S, Schmid I, et al. TRAIL induced survival and proliferation in cancer cells resistant towards TRAIL-induced apoptosis mediated by NF-kappaB[J]. Oncogene, 2003, 22(25): 38 42-52.
|
| [22] |
Shetty S, Gladden JB, Henson ES, et al. Tumor necrosis factorrelated apoptosis inducing ligand(TRAIL) up-regulates death receptor 5 (DR5) mediated by NFkappaB activation in epithelial derived cell lines[J]. Apoptosis, 2002, 7(5): 413-20.
|
| [23] |
Chen X, Kandasamy K, Srivastava RK. Differential roles of RelA (p65) and c-Rel subunits of nuclear factor kappa B in tumor necrosis factor-related apoptosis-inducing ligand signaling[J]. Cancer Res, 2003, 63(5): 1059-66.
|
| [24] |
Seo OW, Kim JH, Lee KS, et al. Kurarinone promotes TRAILinduced apoptosis by inhibiting NF-κB-dependent cFLIP expression in HeLa cells[J]. Exp Mol Med, 2012, 44(11): 653-64.
|
| [25] |
Luo JL, Maeda S, Hsu LC, et al. Inhibition of NF-kappaB in cancer cells converts inflammation- induced tumor growth mediated by TNFalpha to TRAIL-mediated tumor regression[J]. Cancer Cell, 2004, 6(3): 297-305.
|
| [26] |
Zhang JS, Herreros-Vilanueva M, Koenig A, et al. Differential activity of GSK-3 isoforms regulates NF-κB and TRAIL or TNFα induced apoptosis in pancreatic cancer cells[J]. Cell Death Dis, 20 14, 5: e1142.
|
下载:
